Stock comparison
ResMed
Sotera Health
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
RMD
ResMed
Market cap
$29.57B
Sector
Healthcare
SHC
Sotera Health
Market cap
$4.35B
Sector
Healthcare
Overall winner
ResMed RMD
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | RMD | SHC | Winner |
|---|---|---|---|
| Warren Buffett | 64C | 51C | RMD |
| Benjamin Graham | 67B | 78B | SHC |
| Philip Fisher | 67B | 47D | RMD |
| Peter Lynch | 50C | 30F | RMD |
| Joel Greenblatt | 39D | 24F | RMD |
| Charlie Munger | 61C | 54C | RMD |
| Terry Smith | 65B | 52C | RMD |
Side-by-side metrics
| Metric | RMD | SHC |
|---|---|---|
| Market cap | $29.57B | $4.35B |
| P/E (TTM) | 19.6x | 36.9x |
| EV/EBIT | 17.1x | 16.1x |
| ROIC (TTM) | 19.63% | 7.96% |
| Gross margin | 61.69% | 55.01% |
| Net margin | 27.44% | 9.91% |
| Revenue CAGR 5y | 12.64% | 5.72% |
| EPS CAGR 5y | 30.73% | -9.92% |
| Debt / Equity | 0.1x | 3.6x |
| Dividend yield | 1.14% | 0.0% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
RMD leads on
- EPS CAGR 5y30.73%vs -9.92%+132%
- Dividend yield1.14%vs 0.0%+100%
- Debt / Equity0.1xvs 3.6x+96%
- Market cap$29.57Bvs $4.35B+85%
SHC leads on
- EV/EBIT16.1xvs 17.1x+6%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.